Precision Cell Systems (PCS), a cell analysis platform company, and Planet Innovation (PI), a MedTech contract development and manufacturing organization (CDMO), have formed a unique partnership that consolidates cell analysis technologies and then supports them with common commercial and operational infrastructure.
By bringing together complementary cell analysis technologies under its commercial and operational platform, PCS eliminates substantial overhead costs that typically burden emerging technology companies. The model delivers significant efficiencies by centralizing essential functions and provides shared infrastructure for tasks such as capital raising, sales and marketing, product development and manufacturing.
Anup Parikh, CEO of PCS, described how PCS and its partnership with PI are filling a critical void in the market. “There are big gaps in the current venture and innovation models that are causing promising companies with great technologies to struggle. PCS and Planet Innovation are joining forces to remove the strain of raising capital, establishing market channels, creating quality systems and building technical operations. PCS brings its own established funding source and experienced commercial team, which we now combine with the global expertise of Planet Innovation and its world-class operations.”
The partnership will see Planet Innovation provide PCS with extensive product development capacity through its team of over 300 experts, and access to PI’s global manufacturing facilities across the USA, Australia and Singapore. This relieves PCS’s technology teams from the cost of establishing and operating their own facilities, while providing the ability to scale operations up and down as required.
Stuart Elliott, Co-founder and CEO of Planet Innovation, explained, “One of the biggest issues technology companies face is that service providers are not willing to be flexible and turn their services on and off as required. Most service providers are trying to sell the biggest project they can right from the start. This is the opposite to what early-stage companies actually need. Planet Innovation understands this, and so our model is to be as flexible and lean as possible and reduce the cost and time-to-market. As PCS achieves commercial traction PI scales up its manufacturing in support of their growth. It’s a transparent and supportive business model that is completely aligned with the growth of PCS.”
In 2025 PCS completed three acquisitions, S2 Genomics, ORFLO, and BennuBio. Each company individually possesses world-leading technology and now, as part of PCS, they are relieved of substantial commercial and operational burdens and able to maximize their true potential by leveraging PCS’s relationship with PI. PCS is pursuing further acquisitions, targeting complementary technologies for sample preparation, functional cellular and molecular assays, to build a comprehensive cell analysis workflow platform.
